Peritoneal proteoglycans: Much more than ground substance

Peritoneal Dialysis International

Volumn 27, Issue 4, 2007, Pages 375-390

  Yung, Susan ^a,b   Chan, Tak Mao ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b QUEEN MARY HOSPITAL   (Hong Kong)

Author keywords

Biglycan; Decorin; Glycosaminoglycans; Peritoneal fibrosis; Peritoneal inflammation; Perlecan; Proteoglycans; Syndecan

Indexed keywords

BIGLYCAN; CHONDROITIN SULFATE; COLLAGEN; DECORIN; DERMATAN SULFATE; FIBROBLAST GROWTH FACTOR 2; FIBRONECTIN; GAMMA INTERFERON; GLYCOSAMINOGLYCAN; HEPARAN SULFATE; HEPARIN; HEPARIN COFACTOR II; HYALURONIC ACID; KERATAN SULFATE; LOW DENSITY LIPOPROTEIN; LOW MOLECULAR WEIGHT HEPARIN; PERLECAN; PROTEOGLYCAN; RANTES; SCATTER FACTOR; SYNDECAN; SYNDECAN 1; THROMBIN; TRANSFORMING GROWTH FACTOR BETA1; ULINASTATIN;

ANTICOAGULATION; BASEMENT MEMBRANE; DIABETIC NEPHROPATHY; DRUG ELIMINATION; DRUG HALF LIFE; FIBROSIS; GLYCOBIOLOGY; HISTOPATHOLOGY; HOMEOSTASIS; HUMAN; KIDNEY FAILURE; MESOTHELIUM CELL; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PATHOPHYSIOLOGY; PERITONEAL DIALYSIS; PERITONEAL FIBROSIS; PERITONITIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; PROTEOGLYCAN SYNTHESIS; REVIEW; THROMBOEMBOLISM;

EID: 34547614496     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: 10.1177/089686080702700402     Document Type: Review

References (141)

1. Williams JD, Craig KJ, Topley N, Von Ruhland C, Fallon M, Newman GR, et al. Morphologic changes in the peritoneal membrane of patients with renal disease. J Am Soc Nephrol 2002;13:470-9.
2. Holmes CJ, Shockley TR. Strategies to reduce glucose exposure in peritoneal dialysis patients. Perit Dial Int 2000; 20(Suppl 2):S37-41.
3. Gotloib L, Wajsbrot V, Shostak A, Kushnier R. Effect of hyperosmolality upon the mesothelial monolayer exposed in vivo and in situ to a mannitol-enriched dialysis solution. Nephron 1999;81:301-9.
4. Dobbie JW. New concepts in molecular biology and ultrastructural pathology of the peritoneum: their significance for peritoneal dialysis. Am J Kidney Dis 1990;15:97-109.
5. Yung S, Chen XR, Tsang RC, Zhang Q, Chan TM. Reduction of perlecan synthesis and induction of TGF-beta 1 in human peritoneal mesothelial cells due to high dialysate glucose concentration: implication in peritoneal dialysis. J Am Soc Nephrol 2004;15:1178-88.
6. Chan TM, Leung JK, Tsang RC, Liu ZH, Li LS, Yung S. Emodin ameliorates glucose-induced matrix synthesis in human peritoneal mesothelial cells. Kidney Int 2003;64:519-33.
7. Yang AH, Chen JY, Lin JK. Myofibroblastic conversion of mesothelial cells. Kidney Int 2003;63:1530-9.
8. Ha H, Yu MR, Lee HB. High glucose-induced PKC activation mediates TGF-beta 1 and fibronectin synthesis by peritoneal; mesothelial cells. Kidney Int 2001;59:463-70.
9. Ksiazek K, Korybalska K, Jorres A, Witowski J. Accelerated senescence of human peritoneal mesothelial cells exposed to high glucose: the role of TGF-beta1. Lab Invest 2007;87:345-56.
10. Gotloib L, Shostack A, Jaichenko J. Ruthenium-red-stained anionic charges of rat and mice mesothelial cells and basal lamina: the peritoneum is a negatively charged dialyzing membrane. Nephron 1988;48:65-70.
11. Gotloib L, BarSella P, Jaichenko J, Shustack A. Ruthenium-red-stained polyanionic fixed charges in peritoneal microvessels. Nephron 1987;47:22-8.
12. Gotloib L, Shustak A, Jaichenko J. Loss of mesothelial electronegative fixed charges during murine septic peritonitis. Nephron 1989;51:77-83.
13. Galdi P, Shostak A, Jaichenko J, Fudin R, Gotloib L. Protamine sulfate induces enhanced peritoneal permeability to proteins. Nephron 1991;57:45-51.
14. Davies M, Stylianou E, Yung S, Thomas GJ, Coles GA, Williams JD. Proteoglycans of CAPD-dialysate fluid and mesothelium. Contrib Nephrol 1990;85:134-41.
15. Yung S, Thomas GJ, Stylianou E, Williams JD, Coles GA, Davies M. Source of peritoneal proteoglycans. Human peritoneal mesothelial cells synthesize and secrete mainly small dermatan sulfate proteoglycans. Am J Pathol 1995;146:520-9.
16. Yung S, Hausser H, Thomas G, Schaefer L, Kresse H, Davies M. Catabolism of newly synthesized decorin in vitro by human peritoneal mesothelial cells. Perit Dial Int 2004;24:147-55.
17. Staprans I, Piel CF, Felts JM. Analysis of selected plasma constituents in continuous ambulatory peritoneal dialysis effluent. Am J Kidney Dis 1986;7:490-4.
18. Diaz-Buxo JA, Gotloib L. Agents that modulate peritoneal membrane structure and function. Perit Dial Int 2007;27:16-30.
19. Hardingham TE, Fosang AJ. Proteoglycans: many forms and many functions. FASEB J 1992; 6:861-70.
20. Alexopoulou AN, Multhaupt HA, Couchman JR. Syndecans in wound healing, inflammation and vascular biology. Int J Biochem Cell Biol 2007;39:505-28.
21. Proudfoot AE. The biological relevance of chemokine-proteoglycan interactions. Biochem Soc Trans 2006;34:422-6.
22. Border WA, Noble NA, Yamamoto T, Harper JR, Yamaguchi Y, Pierschbacher MD, et al. Natural inhibitor of transforming growth factor-beta protects against scarring in experimental kidney disease. Nature 1992;360:361-4.
23. 2+-dependent phosphorylation of smad2 at serine-240. Biochem J 2002; 362:643-9.
24. Clayton A, Thomas J, Thomas GJ, Davies M, Steadman R. Cell surface heparan sulfate proteoglycans control the response of renal interstitial fibroblasts to fibroblast growth factor-2. Kidney Int 2001; 59:2084-94.
25. Couchman JR. Syndecans: proteoglycan regulators of cell-surface microdomains? Nat Rev Mol Cell Biol 2003; 4:926-37.
26. Schonherr E, Sunderkotter C, Iozzo RV, Schaefer L. Decorin, a novel player in the insulin-like growth factor system. J Biol Chem 2005; 280:15767-72.
27. Taylor KR, Gallo RL. Glycosaminoglycans and their proteoglycans: host-associated molecular patterns for initiation and modulation of inflammation. FASEB J 2006; 20:9-22.
28. Silbert JE, Sugumaran G. Biosynthesis of chondroitin/dermatan sulfate. IUBMB Life 2002; 54:177-86.
29. Parish CR. The role of heparan sulphate in inflammation. Nat Rev Immunol 2006; 6:633-43.
30. Sugahara K, Kitagawa H. Heparin and heparan sulfate biosynthesis. IUBMB Life 2002; 54:163-75.
31. Uyama T, Kitagawa H, Tamura JiJ, Sugahara K. Molecular cloning and expression of human chondroitin N-acetyl-galactosaminyltransferase: the key enzyme for chain initiation and elongation of chondroitin/dermatan sulfate on the protein linkage region tetrasaccharide shared by heparin/ heparan sulfate. J Biol Chem 2002; 277:8841-6.
32. Rohrmann K, Niemann R, Buddecke E. Two N-acetylgalactosaminyltransferase are involved in the biosynthesis of chondroitin sulfate. Eur J Biochem 1985; 148:463-9.
33. Hascall VC, Heinegard D, Wight TN. Proteoglycans. Metabolism and pathology. In: Hay ED, ed. Cell Biology of Extracellular Matrix. New York: Plenum Press; 1991: 149-75.
34. Rees MD, Hawkins CL, Davies MJ. Hypochlorite and superoxide radicals can act synergistically to induce fragmentation of hyaluronan and chondroitin sulphates. Biochem J 2004; 381:175-84.
35. Vilar RE, Ghael D, Li M, Bhagat DD, Arrigo LM, Cowman MK, et al. Nitric oxide degradation of heparin and heparan sulphate. Biochem J 1997; 324(Pt 2):473-9.
36. Karsenty G. An aggrecanase and osteoarthritis. N Engl J Med 2005;353:522-3.
37. Melching LI, Fisher WD, Lee ER, Mort JS, Roughley PJ. The cleavage of biglycan by aggrecanases. Osteoarthritis Cartilage 2006; 14:1147-54.
38. Yasuda T, Tchetina E, Ohsawa K, Roughley PJ, Wu W, Mousa A, et al. Peptides of type ii collagen can induce the cleavage of type II collagen and aggrecan in articular cartilage. Matrix Biol 2006; 25:419-29.
39. Song RH, Tortorella MD, Malfait AM, Alston JT, Yang Z, Arner EC, et al. Aggrecan degradation in human articular cartilage explants is mediated by both ADAMTS-4 and ADAMTS-5. Arthritis Rheum 2007; 56:575-85.
40. Brule S, Charnaux N, Sutton A, Ledoux D, Chaigneau T, Saffar L, et al. The shedding of syndecan-4 and syndecan-1 from Hela cells and human primary macrophages is accelerated by sdf-1/cxcl12 and mediated by the matrix metalloproteinase-9. Glycobiology 2006; 16:488-501.
41. Fosang AJ, Last K, Stanton H, Weeks DB, Campbell IK, Hardingham TE, et al. Generation and novel distribution of matrix metalloproteinase-derived aggrecan fragments in porcine cartilage explants. J Biol Chem 2000; 275:33027-37.
42. Stamenkovic I. Extracellular matrix remodelling: the role of matrix metalloproteinases. J Pathol 2003; 200:448-64.
43. 2-chloride system. Am J Pathol 1993; 143:907-17.
44. Waddington RJ, Moseley R, Embery G. Reactive oxygen species: a potential role in the pathogenesis of periodontal diseases. Oral Dis 2000; 6:138-51.
45. Timpl R. Proteoglycans of basement membranes. Experientia 1993; 49:417-28.
46. Whitelock JM, Murdoch AD, Iozzo RV, Underwood PA. The degradation of human endothelial cell-derived perlecan and release of bound basic fibroblast growth factor by stromelysin, collagenase, plasmin, and heparanases. J Biol Chem 1996; 271:10079-86.
47. Iozzo RV, Cohen IR, Grassel S, Murdoch AD. The biology of perlecan: the multifaceted heparan sulphate proteoglycan of basement membranes and pericellular matrices. Biochem J 1994; 302:625-39.
48. Oda O, Shinzato T, Ohbayashi K, Takai I, Kunimatsu M, Maeda K, et al. Purification and characterization of perlecan fragment in urine of end-stage renal failure patients. Clin Chim Acta 1996; 255:119-32.
49. Raats CJ, Bakker MA, van den Born J, Berden JH. Hydroxyl radicals depolymerize glomerular heparan sulfate in vitro and in experimental nephrotic syndrome. J Biol Chem 1997; 272:26734-41.
50. Roughley PJ, White RJ, Magny MC, Liu J, Pearce RH, Mort JS. Non-proteoglycan forms of biglycan increase with age in human articular cartilage. Biochem J 1993; 295:421-6.
51. Johnstone B, Markopoulos M, Neame P, Caterson B. Identification and characterization of glycanated and nonglycanated forms of biglycan and decorin in the human intervertebral disc. Biochem J 1993; 292:661-6.
52. Witsch-Prehm P, Miehlke R, Kresse H. Presence of small proteoglycan fragments in normal and arthritic human cartilage. Arthritis Rheum 1992; 35:1042-52.
53. Knox SM, Whitelock JM. Perlecan: how does one molecule do so many things? Cell Mol Life Sci 2006; 63:2435-45.
54. Iozzo RV. Basement membrane proteoglycans: from cellar to ceiling. Nat Rev Mol Cell Biol 2005; 6:646-56.
55. Conde-Knape K. Heparan sulfate proteoglycans in experimental models of diabetes: a role for perlecan in diabetes complications. Diabetes Metab Res Rev 2001; 17:412-21.
56. Chen L, Klass C, Woods A. Syndecan-2 regulates transforming growth factor-beta signaling. J Biol Chem 2004; 279:15715-18.
57. Gallagher JT, Turnbull JE. Heparan sulphate in the binding and activation of basic fibroblast growth factor. Glycobiology 1992; 2:523-8.
58. Robinson CJ, Mulloy B, Gallagher JT, Stringer SE. VEGF165-binding sites within heparan sulfate encompass two highly sulfated domains and can be liberated by k5 lyase. J Biol Chem 2006; 281:1731-40.
59. Ornitz DM. FGFs, heparan sulfate and FGFRs: complex interactions essential for development. Bioessays 2000; 22:108-12.
60. Stringer SE. The role of heparan sulphate proteoglycans in angiogenesis. Biochem Soc Trans 2006; 34:451-3.
61. Iozzo RV, San Antonio JD. Heparan sulfate proteoglycans: heavy hitters in the angiogenesis arena. J Clin Invest 2001; 108:349-55.
62. Gallagher JT. Heparan sulfate: growth control with a restricted sequence menu. J Clin Invest 2001; 108:357-61.
63. Lin X, Wei G, Shi Z, Dryer L, Esko JD, Wells DE, et al. Disruption of gastrulation and heparan sulfate biosynthesis in ext1-deficient mice. Dev Biol 2000; 224:299-311.
64. Ringvall M, Ledin J, Holmborn K, van Kuppevelt T, Ellin F, Eriksson I, et al. Defective heparan sulfate biosynthesis and neonatal lethality in mice lacking N-deacetylase/N-sulfotransferase-1. J Biol Chem 2000; 275:25926-30.
65. Bullock SL, Fletcher JM, Beddington RS, Wilson VA. Renal agenesis in mice homozygous for a gene trap mutation in the gene encoding heparan sulfate 2-sulfotransferase. Genes Dev 1998; 12:1894-906.
66. Gotte M, Joussen AM, Klein C, Andre P, Wagner DD, Hinkes MT, et al. Role of syndecan-1 in leukocyte-endothelial interactions in the ocular vasculature. Invest Ophthalmol Vis Sci 2002; 43:1135-41.
67. Gotte M, Bernfield M, Joussen AM. Increased leukocyte-endothelial interactions in syndecan-1-deficient mice involve heparan sulfate-dependent and independent steps. Curr Eye Res 2005; 30:417-22.
68. Vanhoutte D, Schellings MW, Gotte M, Swinnen M, Herias V, Wild MK, et al. Increased expression of syndecan-1 protects against cardiac dilatation and dysfunction after myocardial infarction. Circulation 2007; 115:475-82.
69. Kato M, Saunders S, Nguyen H, Bernfield M. Loss of cell surface syndecan-1 causes epithelia to transform into anchorage-independent mesenchyme-like cells. Mol Biol Cell 1995; 6:559-76.
70. Park PW, Pier GB, Hinkes MT, Bernfield M. Exploitation of syndecan-1 shedding by Pseudomonas aeruginosa enhances virulence. Nature 2001; 411:98-102.
71. Park PW, Foster TJ, Nishi E, Duncan SJ, Klagsbrun M, Chen Y. Activation of syndecan-1 ectodomain shedding by Staphylococcus aureus alpha-toxin and beta-toxin. J Biol Chem 2004; 279:251-8.
72. Chen Y, Hayashida A, Bennett AE, Hollingshead SK, Park PW. Streptococcus pneumoniae sheds syndecan-1 ectodomains through zmpc, a metalloproteinase virulence factor. J Biol Chem 2007; 282:159-67.
73. Rops AL, van der Vlag J, Lensen JF, Wijnhoven TJ, van den Heuvel LP, van Kuppevelt TH, et al. Heparan sulfate proteoglycans in glomerular inflammation. Kidney Int 2004; 65:768-85.
74. Thomas GJ, Shewring L, McCarthy KJ, Couchman JR, Mason RM, Davies M. Rat mesangial cells in vitro synthesize a spectrum of proteoglycan species including those of the basement membrane and interstitium. Kidney Int 1995; 48:1278-89.
75. Lauer ME, Hascall VC, Wang A. Heparan sulfate analysis from diabetic rat glomeruli. J Biol Chem 2007; 282:843-52.
76. Kanwar YS, Linker A, Farquhar MG. Increased permeability of the glomerular basement membrane to ferritin after removal of glycosaminoglycans (heparan sulfate) by enzyme digestion. J Cell Biol 1980; 86:688-93.
77. Kjellen L, Bielefeld D, Hook M. Reduced sulfation of liver heparan sulfate in experimentally diabetic rats. Diabetes 1983; 32:337-42.
78. Williams KJ, Liu ML, Zhu Y, Xu X, Davidson WR, McCue P, et al. Loss of heparan N-sulfotransferase in diabetic liver: role of angiotensin II. Diabetes 2005; 54:1116-22.
79. Morita H, Yoshimura A, Inui K, Ideura T, Watanabe H, Wang L, et al. Heparan sulfate of perlecan is involved in glomerular filtration. J Am Soc Nephrol 2005; 16:1703-10.
80. van der Pijl JW, Daha MR, van den Born J, Verhagen NA, Lemkes HH, Bucala R, et al. Extracellular matrix in human diabetic nephropathy: reduced expression of heparan sulphate in skin basement membrane. Diabetologia 1998; 41:791-8.
81. Skrha J, Perusicova J, Pont'uch P, Oksa A. Glycosaminoglycan sulodexide decreases albuminuria in diabetic patients. Diabetes Res Clin Pract 1997; 38:25-31.
82. Hasengaowa, Kodama J, Kusumoto T, Shinyo Y, Seki N, Nakamura K, et al. Loss of basement membrane heparan sulfate expression is associated with tumor progression in endometrial cancer. Eur J Gynaecol Oncol 2005; 26:403-6.
83. Kodama J, Shinyo Y, Hasengaowa, Kusumoto T, Seki N, Nakamura K, et al. Loss of basement membrane heparan sulfate expression is associated with pelvic lymph node metastasis in invasive cervical cancer. Oncol Rep 2005; 14:89-92.
84. Zhou Z, Wang J, Cao R, Morita H, Soininen R, Chan KM, et al. Impaired angiogenesis, delayed wound healing and retarded tumor growth in perlecan heparan sulfate-deficient mice. Cancer Res 2004; 64:4699-702.
85. Cohen IR, Murdoch AD, Naso MF, Marchetti D, Berd D, Iozzo RV. Abnormal expression of perlecan proteoglycan in metastatic melanomas. Cancer Res 1994; 54:5771-4.
86. Mongiat M, Otto J, Oldershaw R, Ferrer F, Sato JD, Iozzo RV. Fibroblast growth factor-binding protein is a novel partner for perlecan protein core. J Biol Chem 2001; 276:10263-71.
87. Arikawa-Hirasawa E, Watanabe H, Takami H, Hassell JR, Yamada Y. Perlecan is essential for cartilage and cephalic development. Nat Genet 1999; 23:354-8.
88. Costell M, Gustafsson E, Aszodi A, Morgelin M, Bloch W, Hunziker E, et al. Perlecan maintains the integrity of cartilage and some basement membranes. J Cell Biol 1999; 147:1109-22.
89. Garl PJ, Wenzlau JM, Walker HA, Whitelock JM, Costell M, Weiser-Evans MC. Perlecan-induced suppression of smooth muscle cell proliferation is mediated through increased activity of the tumor suppressor pten. Circ Res 2004; 94:175-83.
90. Iozzo RV. The biology of the small leucine-rich proteoglycans. Functional network of interactive proteins. J Biol Chem 1999; 274:18843-6.
91. Schaefer L, Grone HJ, Raslik I, Robenek H, Ugorcakova J, Budny S, et al. Small proteoglycans of normal adult human kidney: distinct expression patterns of decorin, biglycan, fibromodulin, and lumican. Kidney Int 2000; 58:1557-68.
92. Weber IT, Harrison RW, Iozzo RV. Model structure of decorin and implications for collagen fibrillogenesis. J Biol Chem 1996; 271:31767-70.
93. Douglas T, Heinemann S, Bierbaum S, Scharnweber D, Worch H. Fibrillogenesis of collagen types I, II, and III with small leucine-rich proteoglycans decorin and biglycan. Biomacromolecules 2006; 7:2388-93.
94. Reed CC, Iozzo RV. The role of decorin in collagen fibrillogenesis and skin homeostasis. Glycoconj J 2002; 19:249-55.
95. Zhang G, Ezura Y, Chervoneva I, Robinson PS, Beason DP, Carine ET, et al. Decorin regulates assembly of collagen fibrils and acquisition of biomechanical properties during tendon development. J Cell Biochem 2006; 98:1436-49.
96. Roughley PJ. The structure and function of cartilage proteoglycans. Eur Cell Mater 2006; 12:92-101.
97. Danielson KG, Baribault H, Holmes DF, Graham H, Kadler KE, Iozzo RV. Targeted disruption of decorin leads to abnormal collagen fibril morphology and skin fragility. J Cell Biol 1997; 136:729-43.
98. Comalada M, Cardo M, Xaus J, Valledor AF, Lloberas J, Ventura F, et al. Decorin reverses the repressive effect of autocrine-produced TGF-beta on mouse macrophage activation. J Immunol 2003; 170:4450-6.
99. Border WA, Noble NA, Yamamoto T, Tomooka S, Kagami S. Antagonists of transforming growth factor-beta: a novel approach to treatment of glomerulonephritis and prevention of glomerulosclerosis. Kidney Int 1992; 41:566-70.
100. Yamaguchi Y, Mann DM, Ruoslahti E. Negative regulation of transforming growth factor-beta by the proteoglycan decorin. Nature 1990; 346:281-4.
101. Droguett R, Cabello-Verrugio C, Riquelme C, Brandan E. Extracellular proteoglycans modify TGF-beta bio-availability attenuating its signaling during skeletal muscle differentiation. Matrix Biol 2006; 25:332-41.
102. Jahanyar J, Joyce DL, Southard RE, Loebe M, Noon GP, Koerner MM, et al. Decorin-mediated transforming growth factor-beta inhibition ameliorates adverse cardiac remodeling. J Heart Lung Transplant 2007; 26:34-40.
103. Hausser H, Groning A, Hasilik A, Schonherr E, Kresse H. Selective inactivity of TGF-beta/decorin complexes. FEBS Lett 1994; 353:243-5.
104. Schaefer L, Macakova K, Raslik I, Micegova M, Grone HJ, Schonherr E, et al. Absence of decorin adversely influences tubulointerstitial fibrosis of the obstructed kidney by enhanced apoptosis and increased inflammatory reaction. Am J Pathol 2002; 160:1181-91.
105. Isaka Y, Brees DK, Ikegaya K, Kaneda Y, Imai E, Noble NA, et al. Gene therapy by skeletal muscle expression of decorin prevents fibrotic disease in rat kidney. Nat Med 1996; 2:418-23.
106. Scholzen T, Solursh M, Suzuki S, Reiter R, Morgan JL, Buchberg AM, et al. The murine decorin. Complete cDNA cloning, genomic organization, chromosomal assignment, and expression during organogenesis and tissue differentiation. J Biol Chem 1994; 269:28270-81.
107. Xu T, Bianco P, Fisher LW, Longenecker G, Smith E, Goldstein S, et al. Targeted disruption of the biglycan gene leads to an osteoporosis-like phenotype in mice. Nat Genet 1998; 20:78-82.
108. Tomoyasu H, Kikuchi A, Kamo I. Identification of haemopoietic biglycan in hyperplastic thymus associated with myasthenia gravis. J Neuroimmunol 1998; 89:59-63.
109. Kikuchi A, Tomoyasu H, Kido I, Cauda K, Tanaka A, Nonaka I, et al. Haemopoietic biglycan produced by brain cells stimulates growth of microglial cells. J Neuroimmunol 2000; 106:78-86.
110. Shimizu-Hirota R, Sasamura H, Kuroda M, Kobayashi E, Hayashi M, Saruta T. Extracellular matrix glycoprotein biglycan enhances vascular smooth muscle cell proliferation and migration. Circ Res 2004; 94:1067-74.
111. Fries E, Blom AM. Bikunin - not just a plasma proteinase inhibitor. Int J Biochem Cell Biol 2000; 32:125-37.
112. Pugia MJ, Lott JA. Pathophysiology and diagnostic value of urinary trypsin inhibitors. Clin Chem Lab Med 2005; 43:1-16.
113. Zhuo L, Salustri A, Kimata K. A physiological function of serum proteoglycan bikunin: the chondroitin sulfate moiety plays a central role. Glycoconj J 2002; 19:241-7.
114. Capon C, Mizon C, Lemoine J, Rodie-Talbere P, Mizon J. In acute inflammation, the chondroitin-4 sulphate carried by bikunin is not only longer, it is also undersulphated. Biochimie 2003; 85:101-7.
115. Wakahara K, Kobayashi H, Yagyu T, Matsuzaki H, Kondo T, Kurita N, et al. Bikunin suppresses lipopolysaccharide-induced lethality through down-regulation of tumor necrosis factor-alpha and interleukin-1 beta in macrophages. J Infect Dis 2005; 191:930-8.
116. Salustri A, Yanagishita M, Hascall VC. Synthesis and accumulation of hyaluronic acid and proteoglycans in the mouse cumulus cell-oocyte complex during follicle-stimulating hormone-induced mucification. J Biol Chem 1989; 264:13840-7.
117. Suzuki M, Kobayashi H, Tanaka Y, Kanayama N, Terao T. Reproductive failure in mice lacking inter-alpha-trypsin inhibitor (ITI) - ITI target genes in mouse ovary identified by microarray analysis. J Endocrinol 2004; 183:29-38.
118. Zhuo L, Yoneda M, Zhao M, Yingsung W, Yoshida N, Kitagawa Y, et al. Defect in SHAP-hyaluronan complex causes severe female infertility. A study by inactivation of the bikunin gene in mice. J Biol Chem 2001; 276:7693-6.
119. Renvall S. Nucleic acid and sulphated glycosaminoglycan synthesis in the peritoneal membrane and in intra-abdominal adhesions in rat as affected by silica-induced peritonitis. Acta Chir Scand 1979; 145:167-72.
120. Shostak A, Wajsbrot V, Gotloib L. Protective effect of aminoguanidine upon capillary and submesothelial anionic sites. Microvasc Res 2001; 61:166-78.
121. Thomas GJ, Yung S, Davies M. Bikunin present in human peritoneal fluid is in part derived from the interaction of serum with peritoneal mesothelial cells. Am J Pathol 1998; 153:1267-76.
122. Yung S, Coles GA, Williams JD, Davies M. The source and possible significance of hyaluronan in the periconeal cavity. Kidney Int 1994; 46:527-33.
123. Gotte M, Echtermeyer F. Syndecan-1 as a regulator of chemokine function. Scientific World Journal 2003; 3:1327-31.
124. Handel TM, Johnson Z, Crown SE, Lau EK, Proudfoot AE. Regulation of protein function by glycosaminoglycans - as exemplified by chemokines. Annu Rev Biochem 2005; 74:385-410.
125. Li FK, Davenport A, Robson RL, Loetscher P, Rothlein R, Williams JD, et al. Leukocyte migration across human peritoneal mesothelial cells is dependent on directed chemokine secretion and ICAM-1 expression. Kidney Int 1998; 54:2170-83.
126. Trowbridge JM, Gallo RL. Dermatan sulfate: new functions from an old glycosaminoglycan. Glycobiology 2002; 12:117R-25R.
127. Wrenshall LE, Cerra FB, Singh RK, Platt JL. Heparan sulfate initiates signals in murine macrophages leading to divergent biologic outcomes. J Immunol 1995; 154:871-80.
128. Nelimarkka L, Salminen H, Kuopio T, Nikkari S, Ekfors T, Laine J, et al. Decorin is produced by capillary endothelial cells in inflammation-associated angiogenesis. Am J Pathol 2001; 158:345-53.
129. Mateijsen MA, van der Wal AC, Hendriks PM, Zweers MM, Mulder J, Struijk DG, et al. Vascular and interstitial changes in the peritoneum of CAPD patients with peritoneal sclerosis. Perit Dial Int 1999; 19:517-25.
130. Margetts PJ, Gyorffy S, Kolb M, Yu L, Hoff CM, Holmes CJ, et al. Antiangiogenic and antifibrotic gene therapy in a chronic infusion model of peritoneal dialysis in rats. J Am Soc Nephrol 2002; 13:721-8.
131. Buis B, Koomen GC, Imholz AL, Struijk DG, Reddingius RE, Arisz L, et al. Effect of electric charge on the transperitoneal transport of plasma proteins during CAPD. Nephrol Dial Transplant 1996; 11:1113-20.
132. Gotloib L, Shostak A. The relevance of electric charge upon the transperitoneal passage of macromolecular plasma proteins. Nephrol Dial Transplant 1997; 12:621-2.
133. Hetzel GR, Sucker C. The heparins: all a nephrologist should know. Nephrol Dial Transplant 2005; 20:2036-42.
134. Manalaysay MT, Kumano K, Hyodo T, Sakai T. Inhibition of mesothelial cell growth and protein synthesis by heparin. Adv Perit Dial 1995; 11:239-42.
135. Fracasso A, Baggio B, Ossi E, Del Prete D, Bonfante L, Bazzato G, et al. Glycosaminoglycans prevent the functional and morphological peritoneal derangement in an experimental model of peritoneal fibrosis. Am J Kidney Dis 1999; 33:105-10.
136. Pawlaczyk K, Kuzlan-Pawlaczyk M, Anderstam B, Heimburger O, Bergstrom J, Waniewski J, et al. Effects of intraperitoneal heparin on peritoneal transport in a chronic animal model of peritoneal dialysis. Nephrol Dial Transplant 2001; 16:669-71.
137. Sjoland JA, Smith Pedersen R, Jespersen J, Gram J. Intraperitoneal heparin reduces peritoneal permeability and increases ultrafiltration in peritoneal dialysis patients. Nephrol Dial Transplant 2004; 19:1264-8.
138. Sjoland JA, Pedersen RS, Jespersen J, Gram J. Intraperitoneal heparin ameliorates the systemic inflammatory response in PD patients.Nephron Clin Pract 2005; 100:c105-10.
139. Bazargani F, Albrektsson A, Yahyapour N, Braide M. Low molecular weight heparin improves peritoneal ultrafiltration and blocks complement and coagulation. Perit Dial Int 2005; 25:394-404.
140. Breborowicz A, Radkowski M, Knapowski J, Oreopoulos DG. Effects of chondroitin sulphate on fluid and solute transport during peritoneal dialysis in rats. Perit Dial Int 1991; 11:351-4.
141. Breborowicz A, Wieczorowska K, Martis L, Oreopoulos DG. Glycosaminoglycan chondroitin sulphate prevents loss of ultrafiltration during peritoneal dialysis in rats. Nephron 1994; 67:346-50.